Investigation of serum ischemic-modified albumin, galectin-3, paraoxonase-1, and myeloperoxidase activity levels in patients with acute brucellosis

References

• Pappas G, Papadimitriou P, Akritidis N, et al. The new global map of human brucellosis. Lancet Infect Dis. 2006;6(2):91–99. doi:10.1016/S1473-3099(06)70382-6
   PubMed Web of Science ®Google Scholar
• Franco MP, Mulder M, Gilman RH, et al. Human brucellosis. Lancet Infect Dis. 2007;7(12):775–786. doi:10.1016/S1473-3099(07)70286-4
   PubMed Web of Science ®Google Scholar
• Dieffenbach CW, Tramont EC. Innate (general or nonspecific) host defense mechanisms. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 34–42.
   Google Scholar
• Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2010. p. 37–48.
   Google Scholar
• Kocyigit A, Keles H, Selek S, et al. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. Mutat Res. 2005;585(1–2):71–78. doi:10.1016/j.mrgentox.2005.04.012
   PubMed Web of Science ®Google Scholar
• Erdogan S, Tosyali E, Duzguner V, et al. Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010;88(2):218–226. doi:10.1016/j.rvsc.2009.09.002
   PubMed Web of Science ®Google Scholar
• Gidenne S, Ceppa F, Fontan E, et al. Analytical performance of the Albumin Cobalt Binding (ACB) test on the Cobas MIRA Plus analyzer. Clin Chem Lab Med. 2004;42(4):455–461. doi:10.1515/CCLM.2004.079
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Curtis G, Rao N, et al. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem. 2001;268(1):42–47. doi:10.1046/j.1432-1327.2001.01846.x
   PubMedGoogle Scholar
• Collinson PO, Gaze DC. Ischaemia-modified albumin: clinical utility and pitfalls in measurement. J Clin Pathol. 2008;61(9):1025–1028. doi:10.1136/jcp.2007.053363
   PubMed Web of Science ®Google Scholar
• Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49(4):581–585. doi:10.1373/49.4.581
   PubMed Web of Science ®Google Scholar
• Bilgi M, Keser A, Katlandur H, et al. Evaluation of the relationship between microalbuminuria and urine ischemia-modified albumin levels in patients with diabetic nephropathy. J Clin Lab Anal. 2017;31(3):e22058. doi:10.1002/jcla.22058
   PubMed Web of Science ®Google Scholar
• Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230(1):160–167. doi:10.1111/j.1600-065X.2009.00794.x
   PubMed Web of Science ®Google Scholar
• Canales A, Sánchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin (Barc). 2003;121(14):537–548. doi:10.1016/S0025-7753(03)74011-1
   PubMed Web of Science ®Google Scholar
• Frangie C, Daher J. Role of myeloperoxidase in inflammation and atherosclerosis (review). Biomed Rep. 2022;16(6):53. doi:10.3892/br.2022.1536
   PubMed Web of Science ®Google Scholar
• Serefhanoglu K, Taskin A, Turan H, et al. Evaluation of oxidative status in patients with brucellosis. Braz J Infect Dis. 2009;13(4):249–251. doi:10.1590/S1413-86702009000400001
   PubMed Web of Science ®Google Scholar
• Kaya S, Eskazan AE, Elaldi N. Brucellar pericarditis: a report of four cases and review of the literature. Int J Infect Dis. 2013;17:e428–e432. doi:10.1016/j.ijid.2013.01.001
   PubMed Web of Science ®Google Scholar
• Salehi M, Khalili H, Khoshavi M, et al. Brucella myocarditis with unusual clinical features & abnormal cardiac MRI: a case report. ID Cases. 2023;33:e01868.
   Google Scholar
• Sen T, Cağlı K, Gölbaşı Z, et al. Thrombus-in-transit entrapped in a patent foramen ovale: a complication of brucellosis. Turk Kardiyol Dern Ars. 2011;39:487–490. doi:10.5543/tkda.2011.01460
   PubMedGoogle Scholar
• Abid L, Frikha Z, Kallel S, et al. Brucella myocarditis: a rare and life-threatening cardiac complication of brucellosis. Intern Med. 2012;51(8):901–904. doi:10.2169/internalmedicine.51.6379
   PubMed Web of Science ®Google Scholar
• Gürsoy MO, Tursun İ, Alpua M, et al. Brucellosis impairs endothelial functions in chronic symptomatic patients without overt cardiac involvement. Turk Kardiyol Dern Ars. 2015;43(3):242–249. doi:10.5543/tkda.2015.72025
   PubMedGoogle Scholar
• Sessa R, Pietro MD, Filardo S, et al. Infectious burden and atherosclerosis: a clinical issue. World J Clin Cases. 2014;2:240–249. doi:10.12998/wjcc.v2.i7.240
   PubMed Web of Science ®Google Scholar
• Çetin M, Turfan N, Karaman K, et al. The pattern of Tpeak-Tend interval and QTdis, and Pdis in children with brucellosis. J Trop Pediatr. 2019;65(5):474–480. doi:10.1093/tropej/fmy078
   PubMed Web of Science ®Google Scholar
• Ellidag HY, Eren E, Yılmaz N, et al. Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure. Redox Rep. 2014;19(3):118–123. doi:10.1179/1351000213Y.0000000083
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Panagiotakos D, et al. Ischemia modified albumin in relation to pharmacologic stress testing in coronary artery disease. Clin Chim Acta. 2008;396(1–2):58–61. doi:10.1016/j.cca.2008.06.024
   PubMed Web of Science ®Google Scholar
• Chawla R, Goyal N, Calton R, et al. Ischemia modified albumin: a novel marker for acute coronary syndrome. Indian J Clin Biochem. 2006;21(1):77–82. doi:10.1007/BF02913070
   PubMedGoogle Scholar
• Bolatkale M, Duger M, Ülfer G, et al. A novel biochemical marker for community-acquired pneumonia: Ischemia-modified albumin. Am J Emerg Med. 2017;35(8):1121–1125. doi:10.1016/j.ajem.2017.03.018
   PubMed Web of Science ®Google Scholar
• Ustün Y, Engin-Ustün Y, Oztürk O, et al. Ischemia-modified albumin as an oxidative stress marker in preeclampsia. J Matern Fetal Neonatal Med. 2011;24(3):418–421. doi:10.3109/14767058.2010.497879
   PubMed Web of Science ®Google Scholar
• Aydin O, Ellidag HY, Eren E, et al. Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochem Med (Zagreb). 2014;24(3):383–389. doi:10.11613/BM.2014.041
   PubMed Web of Science ®Google Scholar
• Kılıç MÖ, Güldoğan CE, Balamir İ, et al. Ischemia-modified albumin as a predictor of the severity of acute appendicitis. Am J Emerg Med. 2017;35(1):92–95. doi:10.1016/j.ajem.2016.10.010
   PubMed Web of Science ®Google Scholar
• Aslan MH, Karasahin O, Iba Yılmaz S, et al. Thiol/disulphide balance and ischemia modified albumin levels in relapsed brucellosis patients. Eur Res J. 2022;8(1):59–64. doi:10.18621/eurj.813955
   Google Scholar
• Kuwabara I, Liu FT. Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol. 1996;156(10):3939–3944. doi:10.4049/jimmunol.156.10.3939
   PubMed Web of Science ®Google Scholar
• Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28(3):433–440. doi:10.1161/ATVBAHA.107.159160
   PubMed Web of Science ®Google Scholar
• Subhash VV, Ling SSM, Ho B. Extracellular galectin-3 counteracts adhesion and exhibits chemoattraction in Helicobacter pylori-infected gastric cancer cells. Microbiology (Reading). 2016;162(8):1360–1366. doi:10.1099/mic.0.000322
   PubMed Web of Science ®Google Scholar
• Fernandes Bertocchi AP, Campanhole G, Wang PH, et al. A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int. 2008;21(10):999–1007. doi:10.1111/j.1432-2277.2008.00705.x
   PubMed Web of Science ®Google Scholar
• Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015;209(1):13–22. doi:10.1083/jcb.201412052
   PubMed Web of Science ®Google Scholar
• Chen H, Chen C, Fang J, et al. Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis. Heart Fail Rev. 2020;25(2):331–341. doi:10.1007/s10741-019-09858-2
   PubMed Web of Science ®Google Scholar
• Tuegel C, Katz R, Alam M, et al. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. Am J Kidney Dis. 2018;72(4):519–528. doi:10.1053/j.ajkd.2018.03.025
   PubMed Web of Science ®Google Scholar
• Tana FL, Guimarães ES, Cerqueira DM, et al. Galectin-3 regulates proinflammatory cytokine function and favours Brucella abortus chronic replication in macrophages and mice. Cell Microbiol. 2021;23(10):e13375), doi: 10.1111/cmi.13375. Epub 2021 Jul 2. .
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yamaguchi M, Motomura T, et al. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta. 2005;359(1-2):156–162. doi:10.1016/j.cccn.2005.03.046
   PubMed Web of Science ®Google Scholar
• Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38(2):153–163. doi:10.1016/j.freeradbiomed.2004.09.035
   PubMed Web of Science ®Google Scholar
• Mutlu M, Korkmaz MH, Simsek E, et al. Do CO2 and oxidative stress induce cancer?: a brief study about the evaluation of PON 1, CAT, CA and XO enzyme levels on head and neck cancer patients. J. Enzyme Inhib Med Chem. 2019;34(1):459–464. doi:10.1080/14756366.2018.1555157
   PubMed Web of Science ®Google Scholar
• Nessler K, Grzybczak R, Nessler M, et al. Associations between myeloperoxidase and paraoxonase-1 and type 2 diabetes in patients with ischemic heart disease. BMC Cardiovasc Disord. 2022;22(1):521. doi:10.1186/s12872-022-02928-8
   PubMed Web of Science ®Google Scholar
• Ghorbani P, Rezaei Esfahrood Z, et al. Paraoxonase-1, a novel link between periodontitis and ischemic heart disease: A case-control study. Dent Med Probl. 2023;60(1):55–59. doi:10.17219/dmp/152181
   PubMed Web of Science ®Google Scholar
• Istratoaie S, Boroş B, Vesa ŞC, et al. Paraoxonase 1 and atrial fibrillation: is there a relationship? Medicine (Baltimore). 2022;101(46):e31553. doi:10.1097/MD.0000000000031553
   PubMed Web of Science ®Google Scholar
• Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis. 2008;196(1):270–274. doi:10.1016/j.atherosclerosis.2006.10.024
   PubMed Web of Science ®Google Scholar
• Kilic SS, Aydin S, Kilic N, et al. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol. 2005;11:7351–7354. doi:10.3748/wjg.v11.i46.7351
   PubMed Web of Science ®Google Scholar
• Demirpençe O, Sevim B, Yıldırım M, et al. Serum paraoxonase, TAS, TOS and ceruloplasmin in brucellosis. Int J Clin Exp Med. 2014;7(6):1592–1597.
   PubMed Web of Science ®Google Scholar
• Esen R, Aslan M, Kucukoglu ME, et al. Serum paraoxonase activity, total thiols levels, and oxidative status in patients with acute brucellosis. Wien Klin Wochenschr. 2015;127(11-12):427–433. doi:10.1007/s00508-015-0720-z
   PubMed Web of Science ®Google Scholar
• Apostolou F, Gazi IF, Kostoula A, et al. Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res. 2009;50(12):2532–2539. doi:10.1194/jlr.P900063-JLR200
   PubMed Web of Science ®Google Scholar
• Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107(22):2775–2779. doi:10.1161/01.CIR.0000070954.00271.13
   PubMed Web of Science ®Google Scholar
• Melek IM, Erdogan S, Celik S, et al. Evaluation of oxidative stress and inflammation in long term Brucella melitensis infection. Mol Cell Biochem. 2006;293:203–209. doi:10.1007/s11010-006-9243-2
   PubMed Web of Science ®Google Scholar
• Ece A, Gürkan F, Kervancioğlu M, et al. Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure. Pediatr Nephrol. 2006;21(4):545–552. doi:10.1007/s00467-006-0039-0
   PubMed Web of Science ®Google Scholar
• Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110(9):1134–1139. doi:10.1161/01.CIR.0000140262.20831.8F
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol. 2000;7(1):53–58. doi:10.1097/00062752-200001000-00010
   PubMed Web of Science ®Google Scholar
• Malle E, Waeg G, Schreiber R, et al. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem. 2000;267(14):4495–4503. doi:10.1046/j.1432-1327.2000.01498.x
   PubMedGoogle Scholar
• Karahocagil MK, Aslan M, Ceylan MR, et al. Serum myeloperoxidase activity and oxidative stress in patients with acute brucellosis. Clin Biochem. 2012;45(10–11):733–736. doi:10.1016/j.clinbiochem.2012.03.017
   PubMed Web of Science ®Google Scholar